BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28275542)

  • 1. Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication.
    Chung JW; Burciu RG; Ofori E; Shukla P; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2017; 14():417-421. PubMed ID: 28275542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.
    Burciu RG; Ofori E; Shukla P; Pasternak O; Chung JW; McFarland NR; Okun MS; Vaillancourt DE
    Hum Brain Mapp; 2016 Aug; 37(8):2894-903. PubMed ID: 27089850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease.
    Theisen F; Leda R; Pozorski V; Oh JM; Adluru N; Wong R; Okonkwo O; Dean DC; Bendlin BB; Johnson SC; Alexander AL; Gallagher CL
    Neuroimage Clin; 2017; 16():557-563. PubMed ID: 28971007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visuomotor control in patients with Parkinson's disease.
    Chen J; Ho SL; Lee TM; Chang RS; Pang SY; Li L
    Neuropsychologia; 2016 Jan; 80():102-114. PubMed ID: 26529488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct alterations in Parkinson's medication-state and disease-state connectivity.
    Ng B; Varoquaux G; Poline JB; Thirion B; Greicius MD; Poston KL
    Neuroimage Clin; 2017; 16():575-585. PubMed ID: 28971008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-band oscillations in the supplementary motor cortex are modulated by levodopa and associated with functional activity in the basal ganglia.
    Chung JW; Burciu RG; Ofori E; Coombes SA; Christou EA; Okun MS; Hess CW; Vaillancourt DE
    Neuroimage Clin; 2018; 19():559-571. PubMed ID: 29984164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression marker of Parkinson's disease: a 4-year multi-site imaging study.
    Burciu RG; Ofori E; Archer DB; Wu SS; Pasternak O; McFarland NR; Okun MS; Vaillancourt DE
    Brain; 2017 Aug; 140(8):2183-2192. PubMed ID: 28899020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson's disease: an H(2)(15)O PET study.
    Bradberry TJ; Metman LV; Contreras-Vidal JL; van den Munckhof P; Hosey LA; Thompson JL; Schulz GM; Lenz F; Pahwa R; Lyons KE; Braun AR
    Brain Stimul; 2012 Oct; 5(4):605-15. PubMed ID: 22019080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Susceptibility Mapping in Parkinson's Disease.
    Langkammer C; Pirpamer L; Seiler S; Deistung A; Schweser F; Franthal S; Homayoon N; Katschnig-Winter P; Koegl-Wallner M; Pendl T; Stoegerer EM; Wenzel K; Fazekas F; Ropele S; Reichenbach JR; Schmidt R; Schwingenschuh P
    PLoS One; 2016; 11(9):e0162460. PubMed ID: 27598250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease.
    Surova Y; Lampinen B; Nilsson M; Lätt J; Hall S; Widner H; ; van Westen D; Hansson O
    PLoS One; 2016; 11(6):e0157755. PubMed ID: 27362763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Ofori E; Krismer F; Burciu RG; Pasternak O; McCracken JL; Lewis MM; Du G; McFarland NR; Okun MS; Poewe W; Mueller C; Gizewski ER; Schocke M; Kremser C; Li H; Huang X; Seppi K; Vaillancourt DE
    Mov Disord; 2017 Oct; 32(10):1457-1464. PubMed ID: 28714593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease.
    Moro E; Scerrati M; Romito LM; Roselli R; Tonali P; Albanese A
    Neurology; 1999 Jul; 53(1):85-90. PubMed ID: 10408541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease.
    Zhang Y; Wu IW; Buckley S; Coffey CS; Foster E; Mendick S; Seibyl J; Schuff N
    Mov Disord; 2015 Aug; 30(9):1229-36. PubMed ID: 25920732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study.
    Ofori E; Pasternak O; Planetta PJ; Burciu R; Snyder A; Febo M; Golde TE; Okun MS; Vaillancourt DE
    Neurobiol Aging; 2015 Feb; 36(2):1097-104. PubMed ID: 25467638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease.
    Waggan I; Rissanen E; Tuisku J; Matilainen M; Helin S; Parkkola R; Rinne JO; Airas L
    Parkinsonism Relat Disord; 2021 May; 86():40-44. PubMed ID: 33831661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson's disease.
    Arribarat G; Pasternak O; De Barros A; Galitzky M; Rascol O; Péran P
    Parkinsonism Relat Disord; 2019 Aug; 65():146-152. PubMed ID: 31182373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up.
    Gan J; Xie-Brustolin J; Mertens P; Polo G; Klinger H; Mollion H; Benatru I; Henry E; Broussolle E; Thobois S
    J Neurol; 2007 Jan; 254(1):99-106. PubMed ID: 17508144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.